Vor Biopharma Net Income
| VOR Stock | USD 12.67 0.15 1.17% |
As of the 4th of February, Vor Biopharma has the Variance of 104.12, risk adjusted performance of (0.02), and Coefficient Of Variation of (2,243). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vor Biopharma, as well as the relationship between them. Please validate Vor Biopharma market risk adjusted performance and treynor ratio to decide if Vor Biopharma is priced more or less accurately, providing market reflects its prevalent price of 12.67 per share. Given that Vor Biopharma has information ratio of (0.05), we advise you to double-check Vor Biopharma's current market performance to make sure the company can sustain itself at a future point.
Vor Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vor Biopharma's valuation are provided below:There are over one hundred nineteen available fundamental trend indicators for Vor Biopharma, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check Vor Biopharma's current fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -105.2 M | -100 M | |
| Net Loss | -82.9 M | -78.7 M | |
| Net Loss | -105.2 M | -100 M | |
| Net Loss | (39.14) | (41.10) |
Vor | Net Income | Build AI portfolio with Vor Stock |
Evaluating Vor Biopharma's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Vor Biopharma's fundamental strength.
Latest Vor Biopharma's Net Income Growth Pattern
Below is the plot of the Net Income of Vor Biopharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Vor Biopharma financial statement analysis. It represents the amount of money remaining after all of Vor Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Vor Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vor Biopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (116.91 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Vor Net Income Regression Statistics
| Arithmetic Mean | (40,735,181) | |
| Coefficient Of Variation | (116.11) | |
| Mean Deviation | 42,252,330 | |
| Median | (4,152,000) | |
| Standard Deviation | 47,298,742 | |
| Sample Variance | 2237.2T | |
| Range | 113.7M | |
| R-Value | (0.88) | |
| Mean Square Error | 552.4T | |
| R-Squared | 0.77 | |
| Slope | (8,211,184) | |
| Total Sum of Squares | 35794.7T |
Vor Net Income History
Other Fundumenentals of Vor Biopharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Vor Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Vor Biopharma is extremely important. It helps to project a fair market value of Vor Stock properly, considering its historical fundamentals such as Net Income. Since Vor Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vor Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vor Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Vor have expansion opportunities? Factors like these will boost the valuation of Vor Biopharma. If investors know Vor will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Vor Biopharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Vor Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Vor Biopharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Vor Biopharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Vor Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vor Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Vor Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.
Vor Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Vor Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Vor Biopharma.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Vor Biopharma on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Vor Biopharma or generate 0.0% return on investment in Vor Biopharma over 90 days. Vor Biopharma is related to or competes with Fate Therapeutics, Nkarta, Actuate Therapeutics, Alector, Forte Biosciences, PepGen, and Anixa Biosciences. Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell therapies for cancer patients More
Vor Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Vor Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Vor Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 49.36 | |||
| Value At Risk | (11.01) | |||
| Potential Upside | 16.2 |
Vor Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vor Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Vor Biopharma's standard deviation. In reality, there are many statistical measures that can use Vor Biopharma historical prices to predict the future Vor Biopharma's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | 0.6627 |
Vor Biopharma February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.6727 | |||
| Mean Deviation | 7.1 | |||
| Coefficient Of Variation | (2,243) | |||
| Standard Deviation | 10.2 | |||
| Variance | 104.12 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | 0.6627 | |||
| Maximum Drawdown | 49.36 | |||
| Value At Risk | (11.01) | |||
| Potential Upside | 16.2 | |||
| Skewness | (0.96) | |||
| Kurtosis | 6.52 |
Vor Biopharma Backtested Returns
Vor Biopharma owns Efficiency Ratio (i.e., Sharpe Ratio) of close to zero, which indicates the firm had a close to zero % return per unit of risk over the last 3 months. Vor Biopharma exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Vor Biopharma's Coefficient Of Variation of (2,243), variance of 104.12, and Risk Adjusted Performance of (0.02) to confirm the risk estimate we provide. The entity has a beta of -0.7, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Vor Biopharma are expected to decrease at a much lower rate. During the bear market, Vor Biopharma is likely to outperform the market. At this point, Vor Biopharma has a negative expected return of -0.0459%. Please make sure to validate Vor Biopharma's treynor ratio and day typical price , to decide if Vor Biopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.2 |
Insignificant reverse predictability
Vor Biopharma has insignificant reverse predictability. Overlapping area represents the amount of predictability between Vor Biopharma time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vor Biopharma price movement. The serial correlation of -0.2 indicates that over 20.0% of current Vor Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.2 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 2.91 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Vor Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Vor Biopharma reported net income of (116.91 Million). This is 134.26% lower than that of the Biotechnology sector and 266.91% lower than that of the Health Care industry. The net income for all United States stocks is 120.48% higher than that of the company.
Vor Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vor Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vor Biopharma could also be used in its relative valuation, which is a method of valuing Vor Biopharma by comparing valuation metrics of similar companies.Vor Biopharma is currently under evaluation in net income category among its peers.
Vor Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vor Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vor Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Vor Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Vor Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Vor Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vor Biopharma's value.| Shares | Scientech Research Llc | 2025-06-30 | 403.9 K | Blackrock Inc | 2025-06-30 | 374.8 K | Virtu Financial Llc | 2025-06-30 | 275.9 K | Goldman Sachs Group Inc | 2025-06-30 | 180.8 K | Two Sigma Investments Llc | 2025-06-30 | 169.6 K | State Street Corp | 2025-06-30 | 115.9 K | Two Sigma Securities, Llc | 2025-06-30 | 94.4 K | Trustees Of Columbia University In The City Of New York | 2025-06-30 | 91.9 K | Citigroup Inc | 2025-06-30 | 87.5 K | Ra Capital Management, Llc | 2025-06-30 | 39.6 M | 5am Venture Management, Llc | 2025-06-30 | 6.4 M |
Vor Fundamentals
| Return On Equity | -1.25 | ||||
| Return On Asset | -1.44 | ||||
| Current Valuation | 374.29 M | ||||
| Shares Outstanding | 41.52 M | ||||
| Shares Owned By Insiders | 3.56 % | ||||
| Shares Owned By Institutions | 46.00 % | ||||
| Number Of Shares Shorted | 2.19 M | ||||
| Price To Book | 3.14 X | ||||
| EBITDA | (117.66 M) | ||||
| Net Income | (116.91 M) | ||||
| Cash And Equivalents | 151.09 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 31.83 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 12.95 X | ||||
| Book Value Per Share | (246.54) X | ||||
| Cash Flow From Operations | (99.66 M) | ||||
| Short Ratio | 1.60 X | ||||
| Earnings Per Share | (386.86) X | ||||
| Target Price | 44.6 | ||||
| Number Of Employees | 154 | ||||
| Beta | 2.02 | ||||
| Market Capitalization | 531.04 M | ||||
| Total Asset | 142.89 M | ||||
| Retained Earnings | (456.99 M) | ||||
| Working Capital | 77.89 M | ||||
| Net Asset | 142.89 M |
About Vor Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vor Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vor Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vor Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Vor Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Vor Stock
The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.
The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.